Published in Curr Opin Endocrinol Diabetes Obes on October 01, 2014
Visceral adiposopathy: a vascular perspective. Horm Mol Biol Clin Investig (2015) 0.85
Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer (2016) 0.77
Gender-specific association of oxidative stress and inflammation with cardiovascular risk factors in arab population. Mediators Inflamm (2015) 0.77
Effect of phosphorus supplementation on weight gain and waist circumference of overweight/obese adults: a randomized clinical trial. Nutr Diabetes (2015) 0.76
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer. Pharmacogenet Genomics (2015) 0.75
The Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity. Biochem Insights (2017) 0.75
Sex matters: The effects of biological sex on adipose tissue biology and energy metabolism. Redox Biol (2017) 0.75
Weight loss therapy for clinical management of patients with some atherosclerotic diseases: a randomized clinical trial. Nutr J (2015) 0.75
Prostaglandin E2 receptor EP3 regulates both adipogenesis and lipolysis in mouse white adipose tissue. J Mol Cell Biol (2016) 0.75
Calcium Sensing Receptor as a Novel Mediator of Adipose Tissue Dysfunction: Mechanisms and Potential Clinical Implications. Front Physiol (2016) 0.75
Nuchal Skinfold Thickness: A Novel Parameter for Assessment of Body Composition in Childhood Craniopharyngioma. J Clin Endocrinol Metab (2016) 0.75
Dietary olive oil induces cannabinoid CB2 receptor expression in adipose tissue of Apc(Min/+) transgenic mice. Nutr Healthy Aging (2016) 0.75
Four-Year Changes in Visceral Fat Mass and the Risk of Developing Proteinuria in the General Population. PLoS One (2015) 0.75
Combined effect of body mass index and waist-height ratio on incident diabetes; a population based cohort study. J Clin Biochem Nutr (2017) 0.75
FAM3A enhances adipogenesis of 3T3-L1 preadipocytes via activation of ATP-P2 receptor-Akt signaling pathway. Oncotarget (2017) 0.75
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med (2013) 9.66
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A (2009) 5.64
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol (2013) 5.24
The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem (2008) 2.72
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab (2004) 2.59
Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord (2004) 2.40
Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med (2012) 2.07
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther (2008) 1.95
Adiposopathy is "sick fat" a cardiovascular disease? J Am Coll Cardiol (2011) 1.95
Subcutaneous adipocyte size and body fat distribution. Am J Clin Nutr (2008) 1.80
The case of visceral fat: argument for the defense. J Clin Invest (2004) 1.73
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients (2013) 1.73
Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am J Physiol Endocrinol Metab (2009) 1.63
Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. Gastroenterology (2010) 1.62
The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One (2010) 1.37
Beyond BMI: The "Metabolically healthy obese" phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality -- a systematic review. BMC Public Health (2014) 1.31
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.31
Fat depots, free fatty acids, and dyslipidemia. Nutrients (2013) 1.30
Perivascular adipose tissue: more than just structural support. Clin Sci (Lond) (2012) 1.29
Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab (2013) 1.27
"Sick fat," metabolic disease, and atherosclerosis. Am J Med (2009) 1.27
'Metabolically healthy obesity': origins and implications. Mol Aspects Med (2012) 1.27
Adipose tissue dysfunction in nascent metabolic syndrome. J Obes (2013) 1.26
Fatty acid transport proteins, implications in physiology and disease. Biochim Biophys Acta (2011) 1.26
Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-κB stress pathway. Diabetes (2011) 1.24
Obesity and kidney disease: potential mechanisms. Semin Nephrol (2013) 1.16
Increased whole-body adiposity without a concomitant increase in liver fat is not associated with augmented metabolic dysfunction. Obesity (Silver Spring) (2010) 1.14
Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab (2012) 1.06
Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol (2011) 1.00
Adipocyte mitochondrial function is reduced in human obesity independent of fat cell size. J Clin Endocrinol Metab (2013) 0.98
Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care (2013) 0.96
Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes (2006) 0.96
Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. J Obes (2013) 0.95
Inflexibility in intramuscular triglyceride fractional synthesis distinguishes prediabetes from obesity in humans. Obesity (Silver Spring) (2009) 0.93
Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies. Am J Cardiol (2012) 0.92
Adiposopathy, "sick fat," Ockham's razor, and resolution of the obesity paradox. Curr Atheroscler Rep (2014) 0.90
Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? Int J Clin Pract (2009) 0.90
Anthropometric measurements and diabetes mellitus: clues to the "pathogenic" and "protective" potential of adipose tissue. Metab Syndr Relat Disord (2010) 0.89
Systemic effects of white adipose tissue dysregulation and obesity-related inflammation. Obesity (Silver Spring) (2010) 0.89
The mechanisms linking adiposopathy to type 2 diabetes. Front Med (2013) 0.86
Adipose tissue changes in obesity. Biochem Soc Trans (2005) 0.85
The role of cardiac fat in insulin resistance. Curr Opin Clin Nutr Metab Care (2012) 0.85
Effect of ritonavir and atazanavir on human subcutaneous preadipocyte proliferation and differentiation. Antiviral Res (2010) 0.83
Modulation of adipocyte lipoprotein lipase expression as a strategy for preventing or treating visceral obesity. Med Hypotheses (2001) 0.82
Induction of adipocyte hyperplasia in subcutaneous fat depot alleviated type 2 diabetes symptoms in obese mice. Obesity (Silver Spring) (2014) 0.80
Adipocyte size is associated with NAFLD independent of obesity, fat distribution, and PNPLA3 genotype. Obesity (Silver Spring) (2013) 0.78
Pharmacotherapy of obesity: currently marketed and upcoming agents. Am J Cardiovasc Drugs (2002) 0.78